GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

Emma Walmsley has also been busy shaking up the company and has replaced 50 top managers, around 40% of the company’s management. Pfizer said in October that it is considering selling its ...

Walmsley, the only woman CEO of a major pharma company, told Fortune at the time that GSK was working on building its vaccine portfolio. That’s not the only avenue where GSK is growing.

Walmsley stated that GSK's renewed focus on oncology is a strategic move to expand its specialty medicines portfolio. The company has plans to advance the IDRx drug to late-stage trials within the ...

CEO Emma Walmsley says. Speaking at the CEO Times Summit in London, Walmsley highlights the U.K. pharmaceutical company's refocused R&D strategy, with investments concentrated in the U.K., U.S ...

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on ...